Aptahem AB (publ) announce today that applications to the regulatory authority and the central ethics committee in The Netherlands have been submitted for approval to initiate a clinical phase 1 study with its drug candidate Apta-1. Aptahem develop Apta-1...
Read MoreBioStock published an article on 16 September 2022 about Aptahem, which can be read in full below. Sepsis is a life-threatening condition. Every year, 50 million people are affected by sepsis, of which 11 million die. Despite this, a...
Read MoreBioStock published an article on 31 August 2022 about Aptahem, which can be read in full below. Malmö-based biotech Aptahem, which is developing the drug candidate Apta-1 as a new type of emergency treatment for sepsis, released its Q2...
Read MoreBioStock published an article on 15 August 2022 about Aptahem, which can be read in full below. BioStock reached out to Malmö company Aptahem, which is developing an emergency treatment for sepsis. The biotech points out that they continue...
Read MoreAptahem AB (publ) announces today that the final study report from the GLP (Good Laboratory Practice) toxicology and safety studies has been finalized. The report confirms the previously communicated preliminary results regarding positive safety profile for Apta-1. The GLP...
Read MoreBioStock published an article on 17 June 2022 about Aptahem, which can be read in full below. Aptahem has appointed Dr Ingela Hallberg as the new Medical Director. The company is thus putting another piece of the puzzle in...
Read MoreAptahem (publ) announces today that Ingela Hallberg has been appointed new Chief Medical Officer (CMO) in the company as of 1 June 2022. Ingela has long and solid experience from the pharmaceutical industry where she has held senior management...
Read MoreBioStock published an article on 23 May 2022 about Aptahem, which can be read in full below. Aptahem has entered into an agreement with a clinical contract research organisation in the Netherlands for the implementation of the upcoming phase...
Read MoreAptahem (publ) announces today that the company has signed an agreement with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to perform the upcoming phase 1 studies with Apta-1. By entering...
Read MoreAptahem (publ) today announce that the company enters a consortium together with Örebro University, Attgeno AB, BioReperia AB, Buzzard Pharmaceuticals AB, Lipum AB, Thermo Fisher Scientific och Toleranzia AB. The newly established consortium aims to evaluate new treatments to...
Read More